SCHEMBL2420079

SCHEMBL2420079

O=C(Cc1ccc(Cl)cc1)Nc1n[nH]c2sc(C(=O)Nc3ccccc3Cl)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
THRB P10828 2/20 0.47
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
CDK1 P06493 3/20 0.44
CDK2 P24941 3/20 0.44
MAPK1 P28482 2/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
CDK4 P11802 1/20 0.42
NPY5R Q15761 1/20 0.41
PLK4 O00444 1/20 0.41
AURKA O14965 1/20 0.41
PDPK1 O15530 1/20 0.41
DYRK3 O43781 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
CHEK2 O96017 1/20 0.41
RET P07949 1/20 0.41
FGFR1 P11362 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2417194 0.94 MAPT (0.48) MAPTTHRBKMT2AMEN1CDK2
SCHEMBL2415397 0.93 THRB (0.44) MAPTTHRBKMT2AMEN1CDK1
SCHEMBL2416097 0.93 KMT2A (0.45) MAPTTHRBKMT2AMEN1CDK1
SCHEMBL2418738 0.91 NPC1 (0.47) MAPTTHRBKMT2AMEN1CDK2
SCHEMBL2417089 0.91 SMN1; SMN2 (0.45) MAPTTHRBKMT2AMEN1CDK1
SCHEMBL2418889 0.90 MAPT (0.47) MAPTTHRBKMT2AMEN1KDR
SCHEMBL2415476 0.89 CDK2 (0.44) MAPTKMT2AMEN1CDK1CDK2
SCHEMBL2419145 0.88 MEN1 (0.51) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL2414551 0.88 THRB (0.43) MAPTTHRBKMT2AMEN1CDK1
SCHEMBL2417616 0.85 KMT2A (0.43) MAPTKMT2AMEN1CDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541378-B2 Condensed heterocyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-06-02 US claimed
EP-1530573-B1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-03-19 EP claimed
US-8017643-B2 Condensed heterocyclic pyrazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-13 US disclosed
US-20100286223-A1 Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors PFIZER ITALIA S.R.L. (IT) 2010-11-11 US disclosed
US-7541378-B2 Condensed heterocyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-06-02 US disclosed
EP-1530573-B1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-03-19 EP disclosed
US-20060122249-A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2006-06-08 US disclosed
EP-1530573-A1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2005-05-18 EP disclosed
WO-2004013146-A1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A (IT) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286223-A1 Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors CDK2, MAP3K19, MAP3K15 MAPT 2293/4885THRB 2599/4885KMT2A 1298/4885
US-20060122249-A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors CDK2, MAP3K19, MAP3K15 MAPT 2293/4885THRB 2599/4885KMT2A 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.